Background: Due to the rising incidence of diabetes mellitus, hypertension, other non-communicable diseases, and the aging of the population, chronic kidney disease (CKD), considered a severe ailment, is now at epidemic levels. Materials & Method: This is a retrospective study, using data from the General Medicine Department and Renal Unit Database. It included all the patients between Jan 2018 and Dec 2022 who were admitted in the General Medicine wards for treatment of CKD Stages 3a to 5. The data collection focused on parameters such as improvement and reduction rates in gross clinical variables as recorded in patient’s medical records; biochemical urinalysis reports, Complete blood count (CBC) as well as renal function test (RFT); in addition to mineral and bone disorder parameters in regression over the course of treatment such as drug therapy (I.V or I.M or Oral), dialysis and/or transplant in the in-patient setting. The findings were grouped into categories and percentages, described in ratio and proportions. Mean, median, mode for the data was calculated using univariate analysis wherever feasible and necessary. Significance was considered if p < 0.05. Results: Total 384 patients diagnosed with CKD Stages 3a to 5 were enrolled in the study. Majority of the patients were in the 51 to 60 years age group (126, 32.8%). 78.4% were male and 21.6% were female. Furthermore, 82.6% were treated with only dialysis and these patients were categorized as Group D. Remaining 16.9% were on dialysis and anti-hypertensive medicine, 0.3% were on dialysis and antibiotics and another 0.3% were on dialysis, antihypertensives and oral hypoglycemic agents where these patients were categorized as Group O. No statistically significant difference was found between both groups when the mode of treatments were compared (p>0.05). Conclusion: The preferred treatment modalities showed good prognosis and were all equally effective in improving CKD.